EP1250170A1 - Shrinkage of dilatations in the body - Google Patents
Shrinkage of dilatations in the bodyInfo
- Publication number
- EP1250170A1 EP1250170A1 EP01902144A EP01902144A EP1250170A1 EP 1250170 A1 EP1250170 A1 EP 1250170A1 EP 01902144 A EP01902144 A EP 01902144A EP 01902144 A EP01902144 A EP 01902144A EP 1250170 A1 EP1250170 A1 EP 1250170A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- lumen
- dilatation
- catheter
- tissue
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000018672 Dilatation Diseases 0.000 title abstract description 63
- 238000011282 treatment Methods 0.000 claims abstract description 79
- 238000000034 method Methods 0.000 claims abstract description 52
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 13
- 210000001519 tissue Anatomy 0.000 claims description 43
- 239000000126 substance Substances 0.000 claims description 16
- 238000010438 heat treatment Methods 0.000 claims description 10
- 210000004204 blood vessel Anatomy 0.000 claims description 5
- 210000005070 sphincter Anatomy 0.000 claims description 5
- 238000002604 ultrasonography Methods 0.000 claims description 4
- 206010002329 Aneurysm Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000031513 cyst Diseases 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 206010011732 Cyst Diseases 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 210000005095 gastrointestinal system Anatomy 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 230000003902 lesion Effects 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims description 2
- 239000012982 microporous membrane Substances 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 230000002207 retinal effect Effects 0.000 claims description 2
- 206010040882 skin lesion Diseases 0.000 claims description 2
- 231100000444 skin lesion Toxicity 0.000 claims description 2
- 210000002229 urogenital system Anatomy 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 238000000053 physical method Methods 0.000 claims 4
- 210000005036 nerve Anatomy 0.000 claims 3
- 239000006260 foam Substances 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 231100000252 nontoxic Toxicity 0.000 claims 2
- 230000003000 nontoxic effect Effects 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000000260 Warts Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000000975 bioactive effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000008472 epithelial growth Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 238000001139 pH measurement Methods 0.000 claims 1
- 201000010153 skin papilloma Diseases 0.000 claims 1
- 239000000344 soap Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 238000012800 visualization Methods 0.000 claims 1
- 239000012530 fluid Substances 0.000 abstract description 64
- 210000001124 body fluid Anatomy 0.000 abstract description 5
- 239000010839 body fluid Substances 0.000 abstract description 5
- 210000002919 epithelial cell Anatomy 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 238000005728 strengthening Methods 0.000 abstract description 2
- 238000002679 ablation Methods 0.000 description 4
- 239000004020 conductor Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000002594 fluoroscopy Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000004324 lymphatic system Anatomy 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 229920004934 Dacron® Polymers 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920000271 Kevlar® Polymers 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000004761 kevlar Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1011—Multiple balloon catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1052—Balloon catheters with special features or adapted for special applications for temporarily occluding a vessel for isolating a sector
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1095—Balloon catheters with special features or adapted for special applications with perfusion means for enabling blood circulation while the balloon is in an inflated state or in a deflated state, e.g. permanent by-pass within catheter shaft
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/36—General characteristics of the apparatus related to heating or cooling
Definitions
- This invention relates to techniques for shrinking dilatations in the body by localized tissue modification
- a dilatation is an abnormally enlarged or distended segment of an otherwise patent biological lumen or conduit, such as the gastrointestinal, genito-urmary, pulmonary, vascular, or other systems in the body Dilatations may also occur at other places within the body, such as in the nervous system, the eyes, or the skin
- the degree of enlargement, the length, and the significance of the dilatation may differ greatly between particular dilatations, and is responsive to the natuie of the lumen subject to the dilatation
- Various etiological factors might be responsible for the development or exacerbation of any particular dilatation, these may include, for example, blockage, stenosis, infection, inflammation, trauma (whether external, internal, or surgical), or cancer
- One or more of these factors causes the affected lumen to enlarge, expand or distend, with consequential compromise of the function of the lumen and increased danger of rupture of the lumen
- Treatment of dilatations is aimed at restoration of normal intraluminal diameter and strengthening of the lumen walls Because of the presence of abnormal or diseased tissue at the dilatation, surgical treatment by endoscopic or by open surgical techniques often poses extra difficulties and has significant morbidity Moreover, because the tissue of the lumen wall at the dilatation is already diseased, it often generates further scarring and fibrosis when it heals after surgery, which can lead to recurrence of the dilatation
- a method and system for treatment of dilatations such as for example vascular aneurysms, which uses existing tissue, which promotes healing of existing tissue, and which helps to prevent recurrence of the dilatation
- dilatations such as for example vascular aneurysms
- a saline solution is introduced into the occluded region and perfused into the lumen-wall tissue of the occluded region
- radio frequency (“RF") or other energy is emitted controllably to heat and soften only the lumen-wall tissue perfused with saline solution in the occluded region of the dilatation
- the dilatation is shrunk by application of a chilled saline solution and a vacuum
- additional RF or other energy is emitted to ablate, further shrink, and harden only the lumen-wall tissue perfused with saline solution in the occluded region of the dilatation, all without destroying the inner surface of the lumen or
- tissue such as cysts, gangrenous tissue, necrotic tissue or tumors, including shrinking, reducing, destroying and removing such tissue, from any system of the body including the cardiovascular system, the lymphatic system, the cardiopulmonary system, the gastrointestinal system (head and neck, esophagus, stomach, intestines, colon, rectum), the urogenital system, the nervous system, particular organs such as the kidney or prostate, retinal lesions and skin lesions
- the invention provides a method and system for treatment of dilatations using a catheter for precise application of RF energy to subsurface lumen-wall tissue to reduce the diameter of an enlarged portion of any sphincter or lumen of the body
- the catheter is introduced into a lumen of the body and directed to the vicinity of the dilatation to be treated, the position of the catheter is fixed and the dilatation is occluded between two inflatable balloons, and a first saline solution is introduced into the occluded region at a temperature and pressure sufficient to perfuse the saline solution into tissue of the lumen wall in the occluded region, the first saline solution is then exchanged for a chilled salme solution, a vacuum is applied, and RF energy is emitted at a frequency which is absorbed more readily by the lumen-wall tissue which has absorbed the first saline solution, thereby shrinking, ablating and hardening the lumen-wall tissue of the dilatation without effecting either the mucosal
- Figure 3 shows a mesh of direct contact bipolar electrodes that have been expanded by and about the optional intermediate treatment balloon.
- Figure 4 shows a catheter tip assembly with monopolar ring electrodes that can be used with or without the optional intermediate treatment balloon.
- Figure 5 shows a catheter tip assembly with bipolar ring electrodes that can be used with or without the optional intermediate treatment balloon.
- Figure 6 shows a flow chart of a method of operation for the catheter.
- a catheter 100 includes a tip assembly 101 and a multi-lumen tube 102 coupled thereto.
- the tip assembly 101 comprises a generally prolate spheroid with a long axis 103.
- the tip assembly 101 includes a proximal end 109 and a distal end 1 10, with the proximal end 109 coupled to the multi-lumen tube 102 for coupling control signals, energy and fluids between the tip assembly 101 and a control system (not show).
- the tip assembly 101 is disposed in a dilatation 1 13 of a lumen 104 of the body of a patient with the long axis 103 approximately parallel to lumen walls 105.
- the dilatation 1 13 in the lumen 104 may comprise an aneurysm in a blood vessel.
- the dilatation 1 13 may comprise any sphincter or lumen of the body.
- the tip assembly 101 may comprise another shape, such as curved or needle-like disposed for fitting within a particular body cavity, for avoiding a particular body structure, or for adaptation to a particular body structure.
- the tip assembly 101 may comprise a curved, needle-like shape adapted to a surface curvature of an eyeball so that the tip assembly 101 can be inserted under an eyelid.
- the catheter tube 102 comprises a relatively inert and nonconducting substance such as woven dacron.
- the catheter tube 102 may comprise other relatively inert and nonconducting materials such as kevlar, nylon, or plastic, or combinations thereof.
- the tip assembly 101 may include one or more marker elements preferably disposed at or near the distal end 1 10 of the tip assembly 101 and/or at or near the proximal end 109 of the tip assembly 101, which are noticeable using fluoroscopy or ultrasound or other suitable means.
- a radiologist or surgeon can position the catheter 100 relative to the dilatation 1 13 without any requirement for a camera or other optical equipment disposed in or near the dilatation 1 13.
- a camera or other optical equipment may be included.
- the tip assembly 101 includes at least one port 1 1 1 , from which a treatment fluid 1 12 may flow out of the tip assembly 101 and into or near the dilatation 1 13, and at least one suction port 1 14.
- the port 1 1 1 1 and suction port 1 14 are further disposed to comprise a fluid circulation system, wherein at least one port 1 1 1 is a fluid outlet port and at least one suction port 1 14 is a fluid inlet port.
- the fluid circulation system is disposed for circulating fluid in the region of the dilatation 113 near the catheter 100, such as for delivering fluid for cooling the region and for removing other fluid for aspirating the region.
- the port 1 1 1 is disposed for delivering substantially equal amounts of treatment fluid 112 in all directions from the tip assembly 101.
- the port 1 11 may be disposed for delivering differing amounts of treatment fluid 112 in an asymmetrical pattern near the tip assembly 101, either by a tering the shape of a single port 111 or by including a plurality of ports 111.
- there could be a single port 1 1 1 alternatively there could be a plurality of ports 1 1 1 each substantially the same size but with a variable number of ports 1 1 1 located in various locations about the tip assembly 101, and further alternatively there may be ports 1 11 of substantially different sizes.
- the ports 1 1 1 are each open at all times, in alternative embodiments, they may be subject to a microscopic mechanical device or other technique for closing some or all of them at selected times.
- the ports 111 are also disposed for removing fluids from the lumen
- the ports 1 1 1 may handle all fluid delivery and removal during treatment, and no suction ports 1 14 are needed. All of the ports 1 1 1 may be coupled to a single lumen in the catheter tube 102, or some ports 1 1 1 may be coupled to one lumen and other ports 1 1 1 coupled to another lumen in the catheter tube 102. Preferably, movement of treatment fluid 1 12 through the ports 1 1 1 is controllable so that, according to the needs of a treatment regimen, at a given time all of the ports 1 1 1 may deliver treatment fluid 112, all of the ports 1 1 1 may remove treatment fluid 1 12 and/or other fluids, or some ports 1 1 1 may deliver treatment fluid 1 12 while other ports 1 1 1 simultaneously remove treatment fluid 1 12 and/or other fluids. In an alternative embodiment, separately controllable suction ports 1 14, coupled to a lumen in the catheter tube 102, may also be located on an exterior surface of the tip assembly 101, and in combination with the ports 1 1 1 may comprise a fluid circulation system.
- the tip assembly 101 may also include at least one temperature sensor 1 15 and at least one pressure sensor 116, both preferably disposed at or near the surface of the tip assembly 101.
- the sensors are coupled using the catheter tube 102 to a control system (not shown) and to an operator presentation device (not shown).
- the sensors provide signals to the control system for feedback control, and to the operator presentation device for presenting information to an operator.
- the temperature sensor 1 15 comprises a plurality of temperature sensors, such as thermistors or thermocouples, and the control system provides feedback control to maintain various temperatures selected by the operator.
- the operator presentation device comprises a temperature reporting gauge.
- other and further sensor signals, feedback control, and presentation signals would be useful, and are within the scope and spirit of the invention.
- the pressure sensor 1 16 comprises a plurality of pressure sensors, and the control system provides feedback control to maintain various pressures selected by the operator.
- the operator presentation device comprises a pressure reporting gauge.
- the tip assembly 101 may be fitted with other and further equipment.
- equipment may include a camera or other light-gathering device, either for aiding a surgeon in manipulating the catheter 100 (e.g., maneuvering the tip assembly 101 to reach the dilatation 1 13), or for photographically recording the action of the catheter 100 and associated equipment; a laser or other device for ablating or reducing obstructions; or other equipment. Coupling cameras or other light- gathering devices, or lasers or other ablating or reducing devices, to catheters 100 is known in the art of medical devices.
- treatment fluid is used generically to mean and refer to any fluid which can act as an electrolyte.
- the treatment fluid 1 12 is a saline solution.
- the treatment fluid 1 12 may be collagen, a collagenous fluid, or any other fluid which is readily absorbed by the tissue of the lumen walls 104 and which readily absorbs RF energy.
- the treatment fluid 1 12 may comprise medicine, water, or a fluid which is relatively inert and non-bioreactive but heat conductive.
- the tip assembly 101 also includes a first occluding balloon 106 preferably disposed at or near a proximal end 109 of the tip assembly 101 , and a second occluding balloon 107 preferably disposed at or near the distal end 1 10 of the tip assembly 101.
- the occluding balloons 106 and 107 are disposed so that when inflated, and in combination with the body of the tip assembly 101, they form a gas-tight or fluid-tight seal against the lumen walls 105 and seal off the portion of the dilatation 1 13 to be treated from other portions of the lumen 104.
- the occluding balloons 106 and 107 preferably comprise ring-shaped annular balloons; however, in an alternative embodiment, the distal occluding balloon 107 may comprise a spherical or ellipsoidal balloon disposed at the distal end 1 10 of the tip assembly 101 in such a manner that when inflated it surrounds the catheter 100 and makes a gas-tight or fluid-tight seal against the lumen walls 104.
- both occluding balloons 106 and 107 are coupled to a single lumen in the catheter tube 102 disposed for delivery of an inflation fluid from a source (not shown).
- the occluding balloons 106 and 107 are coupled to separate lumina in the catheter tube 102 disposed for delivery of inflation fluid from sources (not shown), so that the occluding balloons 106 and 107 may be inflated independently of each other.
- at least one occluding balloon 106 or 107 is disposed to anchor the catheter 100 at a selected location within the lumen 104; alternatively, both occluding balloons 106 and 107 may be to anchor the catheter 100.
- the balloon used to anchor the catheter 100 may comprise either occluding balloon 106 or 107, or an additional or alternative balloon which is disposed solely or primarily for the purpose of anchoring the catheter 100 into the selected location, again in like manner as the operation of a Foley catheter.
- the tip assembly 101 may also include a third balloon 108 (hereinafter referred to as a "treatment balloon 108"), preferably located intermediately between the occluding balloons 106 and 107, which is inflated using a lumen in the catheter tube 102 for delivery of treatment fluid 1 12 from a source (not shown) through at least one port 1 1 1.
- the treatment balloon 108 is disposed so that when inflated its surface physically comes into contact with the tissue of the lumen walls 105 which comprise the dilatation 1 13.
- the treatment balloon 108 may also include a porous, microporous, or semiporous membrane through which the treatment fluid 1 12 may flow.
- the suction ports 1 14 are preferably located between the outside surface of intermediate treatment balloon 108 and the outside surfaces of the occluding balloons 106 and/or 107, so that the fluid is drawn into the suction ports 1 14 from the occluded region of the lumen 104.
- the suction ports 1 14 may be used either separately or at the same time that treatment fluid 1 12 is delivered from the ports 1 1 1 into the treatment balloon 108.
- the catheter 1 10 also includes at least one electrode, described in more detail below, preferably disposed on the tip assembly 101 between the occluding balloons 106 and 107.
- the electrodes are coupled using the catheter tube 102 to a power source 120.
- the power source 120 provides energy to the electrodes, which emit that energy into the lumen walls 105 of the dilatation 1 13 which have been perfused with the treatment fluid 1 12 so as to affect the lumen walls 105 of the dilatation 1 13.
- Fig. 3 shows a first aspect of the preferred embodiment using direct contact bipolar electrodes 123 to emit RF energy for heating, ablation and/or shrinkage of the dilatation 1 13.
- a plurality of bipolar electrodes 123 are distributed more or less equidistant from each other and disposed so that when the treatment balloon 108 is inflated the electrodes 123 are put in direct contact with the inner surface of the lumen walls 105 in the occluded region of the dilatation 1 13.
- the electrodes 123 are disposed on an expandable conductor mesh 122 surrounding around the treatment balloon 108.
- the conductor mesh 122 and electrodes 123 may be disposed in or near the surface of the treatment balloon 108.
- Fig.4 shows a second aspect of the preferred embodiment using monopolar ring electrodes 124 to emit RF energy for heating, ablation and shrinkage of the dilatation 1 13.
- a plurality of monopolar ring electrodes 124 are disposed repeatedly on or near the surface of the tip assembly 101 between its proximal end 109 and distal end 1 10.
- Fig. 5 shows a third aspect of the preferred embodiment using bipolar ring electrodes 125 to emit RF energy for heating, ablation and shrinkage of the dilatation 1 13.
- a plurality of bipolar ring electrodes 125 are disposec repeatedly on or near the surface of the tip assembly 101 between the proximal end 109 and the distal end 110 of the tip assembly 101.
- many configurations of electrodes and sensors 1 16 may operate under processor control to achieve such effects.
- distances between pairs of ring electrodes 124 may be adjusted, either during manufacture, dynamically before use of the catheter tip 101 , or otherwise.
- the sensors 1 16 may be effective to measure other dynamic features of the treatment fluid 1 12 and lumen-wall tissue of the dilatation 113, such as a localized electrical impedance, a localized fluid flow, or some combination thereof.
- the processor may be effective to control other features of the RF energy, such as a pulse shape or duty cycle of a pulse for RF energy delivery, a frequency for RF energy delivery, a time duration for pulses or time duration between pulses, an order for selection of individual ring electrodes 120 for delivery of RF energy, or some combination thereof.
- Electrodes are coupled to a power source 120 using a conductor 121 in the catheter tube 102.
- the conductor 121 is preferably insulated so as to avoid electrical coupling with the catheter tube 102, the treatment fluid 1 12 or the lumen walls 105.
- the power source 120 provides energy to the electrodes, which emit that energy into the treatment fluid 1 12 and tissue of the lumen walls 105 in the occluded region of the dilatation 1 13.
- RF energy is used generically to mean and refer to any means for heating the treatment fluid 112 and/or tissue of the lumen walls 105, broadly including the application of RF energy in a wide range of frequencies, such as the 300 to 700 MHz frequency described herein as well as other microwave frequencies and other frequencies.
- the means for heating may comprise light.
- the light may be delivered by a laser, light-emitting diode, or other light source coupled to the tip assembly 101.
- the energy source 120 is preferably located outside the lumen 104 and outside the body.
- the RF energy source 120 generates a continuous or pulsed waveform, preferably a sinusoidal waveform or a square waveform, such as an RF energy generator available as a standard product from Radionics Valley Laboratories, a division of Pfizer, Inc.
- the RF energy source 120 supplies about 50 watts of power, distributed to all of the electrodes 123 collectively, and pulsed in a round- robm fashion among the electrodes 123 so as to equally distribute the delivered energy to all positions along the tip assembly 101
- the RF energy source 120 may comprise a processor which is responsive to signals from the sensors 1 16 and to a computed or expected amount of the treatment fluid 1 12 and lumen wall tissue 105 to be treated The processoi computes an effective amount of time and RF energy to deliver to each individual electrode, and controls delivery of RF energy to each individual electrode so as to deliver RF energy to localized points of the treatment fluid 1 12 and lumen wall tissues 105 which have absorbed it
- FIG. 6 shows a flowchart for a method of operation of the catheter 100
- a method 200 of operation for the catheter 100 comprises a sequence of steps between the flow points 201 and 220.
- the method 200 is carried out using the catheter 100, as well as other and furthei equipment which would be cleaily deemed necessary or desirable by those skilled in the art
- the catheter 100 is ready for use to treat dilatation 1 1
- the catheter 100 is inserted into the lumen 104 of a patient at a natural body orifice such as the mouth, anus or urethra
- the catheter 100 may be inserted into a blood vessel near a body surface, such as the jugular vein or carotid artery or other blood vessel in the neck, or may be inserted into the patient at a body structure which is made available during surgery or by virtue of a wound, the body structure may comprise a blood vessel, tubular organ, the lymphatic system, a smus cavity or other ear/nose/throat structure, the intestines, the urethra, a mass of tissue such as a cyst or a fatty deposit, or some other body structure.
- the catheter 100 is maneuvered by an operator (not shown) to a position in the lumen 104 approximately adjacent to the dilatation 113 while the operator views the position of the catheter 100 using fluoroscopy, ultrasound, or other suitable means.
- the occluding balloons 106 and 107 are inflated and the dilatation
- the treatment balloon 108 is inflated with treatment fluid 1 12 exuded from ports 1 1 1 while simultaneously any body fluids in the occluded dilatation 1 13 are removed by suctioning them into suction ports 1 14 disposed on the tip assembly 101 between the occluding balloons 106 and 107 and coupled to a suction lumen in the catheter tube 102. Body fluids are thus removed from the occluded portion of the dilatation 1 13 by the dual action of suction outside the treatment balloon 108 and pressure within it.
- RF energy is emitted by electrodes in the catheter tip assembly 101 at a selected frequency and power level effective to heat the treatment fluid 112 to a temperature at which it is readily absorbable into the tissue of the lumen walls 105.
- the treatment fluid 1 12 in the treatment balloon 108 is pressurized to a selected pressure, effective to cause the treatment fluid 1 12 to exude through the microporous membrane of the treatment balloon and come into contact with the lumen walls 105.
- the heated treatment fluid 112 is suffused into and absorbed by the tissues of the lumen walls 105.
- RF energy is emitted by the electrodes in the catheter tip assembly 101 at a selected frequency and power level effective to preferentially heat tissues of the lumen walls 105 which have absorbed the treatment fluid 1 12.
- cool treatment fluid 112 may be circulated in the occluded portion of the lumen 104 by exuding it from ports 1 1 1 and suctioning it into suction ports 1 14, in order to minimize heating and damage of cells lining the inner surface of the lumen walls 105. Heating of lumen wall tissues 105 continues until they have been softened.
- the heated treatment fluid 112 is removed from the occluded portion of the dilatation 113 via the suction ports 114 and the occluded portion of the dilatation is filled with chilled treatment fluid 112 via the ports 1 11.
- the dilatation 113 is contracted by application of the chilled treatment fluid 112 and by application of a vacuum via the suction ports 1 14 so that dilatation 1 13 shrinks to a diameter within a normal diameter range for the lumen 104.
- additional RF energy may be emitted by the electrodes in the catheter tip assembly 101 at a selected frequency and power level effective to ablate tissues of the lumen walls 105, while chilled treatment fluid 1 12 is circulated by exuding it in via the ports 111 and suctioning it out via the suction ports 1 14 in order to minimize heating and damage of cells lining the inner surface of the lumen walls 105 and remove detritus of ablation.
- the tissues of the lumen walls 105 are hardened in the contracted condition by further application of RF energy and circulation of chilled treatment fluid 112.
- the occluding balloons 106 and 107 and the treatment balloon 108 are deflated.
- the catheter 100 is removed from the body of the patient.
- the dilatation has been treated and should be in a condition for normal operation.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Surgical Instruments (AREA)
- Materials For Medical Uses (AREA)
- Laser Surgery Devices (AREA)
- Electrotherapy Devices (AREA)
- Radiation-Therapy Devices (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
- Lasers (AREA)
Abstract
A method and system for shrinking dilatations of a body, removing excess, weak or diseased tissue, and strengthening remaining tissues of the lumen walls. A catheter is disposed near the dilatation and fixed in position by inflatable occlusion balloons. Body fluids present in the occluded dilatation are evacuated and treatment fluid is exuded under pressure into the dilatation. Pressure is maintained by the treatment fluid while energy is applied by the catheter to heat the treatment fluid, causing the lumen walls to absorb the treatment fluid. Additional energy is then applied so as to preferentially heat the lumen wall tissues which have absorbed the treatment fluid, while at the same time treatment fluid is circulated to cool the inner surface of the lumen walls. The dilatation is occluded, a saline solution is introduced and absorbed into the lumen-wall tissue in the occluded region of the dilatation and then heated by application of radio frequency ("RF") or other energy in order to soften only the lumen-wall tissue of the dilatation, the dilatation is shrunk by application of a chilled saline solution and a vacuum, and additional RF or other energy is emitted to ablate, further shrink, and harden only the lumen-wall tissue of the dilatation, without destroying the inner surface of the lumen or other tissues of the body beyond the lumen walls, thereby promoting the growth of epithelial cells. <IMAGE>
Description
SHRINK GE OF DILATATIONS IN THE BODY
Background of the Invention 1 Field of the Invention
This invention relates to techniques for shrinking dilatations in the body by localized tissue modification
2 Related Art A dilatation is an abnormally enlarged or distended segment of an otherwise patent biological lumen or conduit, such as the gastrointestinal, genito-urmary, pulmonary, vascular, or other systems in the body Dilatations may also occur at other places within the body, such as in the nervous system, the eyes, or the skin The degree of enlargement, the length, and the significance of the dilatation may differ greatly between particular dilatations, and is responsive to the natuie of the lumen subject to the dilatation Various etiological factors might be responsible for the development or exacerbation of any particular dilatation, these may include, for example, blockage, stenosis, infection, inflammation, trauma (whether external, internal, or surgical), or cancer One or more of these factors causes the affected lumen to enlarge, expand or distend, with consequential compromise of the function of the lumen and increased danger of rupture of the lumen
Treatment of dilatations is aimed at restoration of normal intraluminal diameter and strengthening of the lumen walls Because of the presence of abnormal or diseased tissue at the dilatation, surgical treatment by endoscopic or by open surgical techniques often poses extra difficulties and has significant morbidity Moreover, because the tissue of the lumen wall at the dilatation is already diseased, it often generates further scarring and fibrosis when it heals after surgery, which can lead to recurrence of the dilatation
Accordingly, it would be advantageous to provide a method and system for treatment of dilatations, such as for example vascular aneurysms, which uses existing tissue, which promotes healing of existing tissue, and which helps to prevent recurrence of the dilatation This advantage is achieved in an embodiment of the invention
whereby the dilatation is occluded, a saline solution is introduced into the occluded region and perfused into the lumen-wall tissue of the occluded region, radio frequency ("RF") or other energy is emitted controllably to heat and soften only the lumen-wall tissue perfused with saline solution in the occluded region of the dilatation, the dilatation is shrunk by application of a chilled saline solution and a vacuum, additional RF or other energy is emitted to ablate, further shrink, and harden only the lumen-wall tissue perfused with saline solution in the occluded region of the dilatation, all without destroying the inner surface of the lumen or other tissues of the body beyond the lumen wall and thereby promoting growth of epithelial cells in the lumen wall. It would be further advantageous to provide a method and system for treatment of distended, engorged, inflamed or infected tissue such as cysts, gangrenous tissue, necrotic tissue or tumors, including shrinking, reducing, destroying and removing such tissue, from any system of the body including the cardiovascular system, the lymphatic system, the cardiopulmonary system, the gastrointestinal system (head and neck, esophagus, stomach, intestines, colon, rectum), the urogenital system, the nervous system, particular organs such as the kidney or prostate, retinal lesions and skin lesions
Summary of the Invention The invention provides a method and system for treatment of dilatations using a catheter for precise application of RF energy to subsurface lumen-wall tissue to reduce the diameter of an enlarged portion of any sphincter or lumen of the body The catheter is introduced into a lumen of the body and directed to the vicinity of the dilatation to be treated, the position of the catheter is fixed and the dilatation is occluded between two inflatable balloons, and a first saline solution is introduced into the occluded region at a temperature and pressure sufficient to perfuse the saline solution into tissue of the lumen wall in the occluded region, the first saline solution is then exchanged for a chilled salme solution, a vacuum is applied, and RF energy is emitted at a frequency which is absorbed more readily by the lumen-wall tissue which has absorbed the first saline solution, thereby shrinking, ablating and hardening the lumen-wall tissue of the dilatation without effecting either the mucosal surface of the lumen or other tissues of the body beyond the lumen walls, to modify the lumen to with the range of normal and maintain the normal diameter of the lumen and prevent reformation of the dilatation during a healing period
Brief Description of the Drawings Figure 1 shows a catheter inserted into a lumen of the body and located in a dilatation of that lumen, with two occluding balloons and an optional intermediate treatment balloon inflated. Figure 2 is a cross-section of the catheter with the sides of the three inflated balloons cut away, showing additional features of the catheter tip assembly.
Figure 3 shows a mesh of direct contact bipolar electrodes that have been expanded by and about the optional intermediate treatment balloon.
Figure 4 shows a catheter tip assembly with monopolar ring electrodes that can be used with or without the optional intermediate treatment balloon.
Figure 5 shows a catheter tip assembly with bipolar ring electrodes that can be used with or without the optional intermediate treatment balloon.
Figure 6 shows a flow chart of a method of operation for the catheter.
Detailed Description of the Preferred Embodiment
In the following description, a preferred embodiment of the invention is described with regard to preferred structures and process steps. Those skilled in the art would recognize after perusal of this application that embodiments of the invention can be implemented using structures and process steps adapted for treatment of particular regions of the body, and that implementation of the process steps and structures described herein would not require undue experimentation or further invention.
System Elements Catheter and Tip Assembly A catheter 100 includes a tip assembly 101 and a multi-lumen tube 102 coupled thereto. The tip assembly 101 comprises a generally prolate spheroid with a long axis 103. The tip assembly 101 includes a proximal end 109 and a distal end 1 10, with the proximal end 109 coupled to the multi-lumen tube 102 for coupling control signals, energy and fluids between the tip assembly 101 and a control system (not show). The tip assembly 101 is disposed in a dilatation 1 13 of a lumen 104 of the body of a patient with the long axis 103 approximately parallel to lumen walls 105.
In a preferred embodiment, the dilatation 1 13 in the lumen 104 may comprise an aneurysm in a blood vessel. However, in alternative embodiments, the dilatation 1 13 may comprise any sphincter or lumen of the body.
In alternative embodiments, the tip assembly 101 may comprise another shape, such as curved or needle-like disposed for fitting within a particular body cavity, for avoiding a particular body structure, or for adaptation to a particular body structure. For example, the tip assembly 101 may comprise a curved, needle-like shape adapted to a surface curvature of an eyeball so that the tip assembly 101 can be inserted under an eyelid. In a preferred embodiment, the catheter tube 102 comprises a relatively inert and nonconducting substance such as woven dacron. However, in alternative embodiments, the catheter tube 102 may comprise other relatively inert and nonconducting materials such as kevlar, nylon, or plastic, or combinations thereof.
In a preferred embodiment, the tip assembly 101 may include one or more marker elements preferably disposed at or near the distal end 1 10 of the tip assembly 101 and/or at or near the proximal end 109 of the tip assembly 101, which are noticeable using fluoroscopy or ultrasound or other suitable means. With appropriate x-ray or fluoroscopy equipment, a radiologist or surgeon can position the catheter 100 relative to the dilatation 1 13 without any requirement for a camera or other optical equipment disposed in or near the dilatation 1 13. However, in alternative embodiments, such a camera or other optical equipment may be included.
The tip assembly 101 includes at least one port 1 1 1 , from which a treatment fluid 1 12 may flow out of the tip assembly 101 and into or near the dilatation 1 13, and at least one suction port 1 14. In a preferred embodiment, the port 1 1 1 and suction port 1 14 are further disposed to comprise a fluid circulation system, wherein at least one port 1 1 1 is a fluid outlet port and at least one suction port 1 14 is a fluid inlet port. The fluid circulation system is disposed for circulating fluid in the region of the dilatation 113 near the catheter 100, such as for delivering fluid for cooling the region and for removing other fluid for aspirating the region. In a preferred embodiment, the port 1 1 1 is disposed for delivering substantially equal amounts of treatment fluid 112 in all directions from the tip assembly 101. However, in alternative embodiments, the port 1 11 may be disposed for delivering differing amounts of treatment fluid 112 in an asymmetrical pattern near the tip
assembly 101, either by a tering the shape of a single port 111 or by including a plurality of ports 111. For a first xample, while in a preferred embodiment there could be a single port 1 1 1, alternatively there could be a plurality of ports 1 1 1 each substantially the same size but with a variable number of ports 1 1 1 located in various locations about the tip assembly 101, and further alternatively there may be ports 1 11 of substantially different sizes. For a second example, while in a preferred embodiment the ports 1 1 1 are each open at all times, in alternative embodiments, they may be subject to a microscopic mechanical device or other technique for closing some or all of them at selected times. Preferably, the ports 111 are also disposed for removing fluids from the lumen
104. In some embodiments, the ports 1 1 1 may handle all fluid delivery and removal during treatment, and no suction ports 1 14 are needed. All of the ports 1 1 1 may be coupled to a single lumen in the catheter tube 102, or some ports 1 1 1 may be coupled to one lumen and other ports 1 1 1 coupled to another lumen in the catheter tube 102. Preferably, movement of treatment fluid 1 12 through the ports 1 1 1 is controllable so that, according to the needs of a treatment regimen, at a given time all of the ports 1 1 1 may deliver treatment fluid 112, all of the ports 1 1 1 may remove treatment fluid 1 12 and/or other fluids, or some ports 1 1 1 may deliver treatment fluid 1 12 while other ports 1 1 1 simultaneously remove treatment fluid 1 12 and/or other fluids. In an alternative embodiment, separately controllable suction ports 1 14, coupled to a lumen in the catheter tube 102, may also be located on an exterior surface of the tip assembly 101, and in combination with the ports 1 1 1 may comprise a fluid circulation system.
The tip assembly 101 may also include at least one temperature sensor 1 15 and at least one pressure sensor 116, both preferably disposed at or near the surface of the tip assembly 101. The sensors are coupled using the catheter tube 102 to a control system (not shown) and to an operator presentation device (not shown). The sensors provide signals to the control system for feedback control, and to the operator presentation device for presenting information to an operator. In a preferred embodiment, the temperature sensor 1 15 comprises a plurality of temperature sensors, such as thermistors or thermocouples, and the control system provides feedback control to maintain various temperatures selected by the operator. In a preferred embodiment, the operator presentation device comprises a temperature
reporting gauge. However, it would be clear to those skilled in the art that other and further sensor signals, feedback control, and presentation signals would be useful, and are within the scope and spirit of the invention.
In a preferred embodiment, the pressure sensor 1 16 comprises a plurality of pressure sensors, and the control system provides feedback control to maintain various pressures selected by the operator. In a preferred embodiment, the operator presentation device comprises a pressure reporting gauge. However, it would be clear to those skilled in the art that other and further sensor signals, feedback control, and presentation signals would be useful, and are within the scope and spirit of the invention.
In alternative embodiments, the tip assembly 101 may be fitted with other and further equipment. Such equipment may include a camera or other light-gathering device, either for aiding a surgeon in manipulating the catheter 100 (e.g., maneuvering the tip assembly 101 to reach the dilatation 1 13), or for photographically recording the action of the catheter 100 and associated equipment; a laser or other device for ablating or reducing obstructions; or other equipment. Coupling cameras or other light- gathering devices, or lasers or other ablating or reducing devices, to catheters 100 is known in the art of medical devices.
Treatment Fluid
As used herein, the term "treatment fluid" is used generically to mean and refer to any fluid which can act as an electrolyte. In the preferred embodiment, the treatment fluid 1 12 is a saline solution. However, in alternative embodiments, the treatment fluid 1 12 may be collagen, a collagenous fluid, or any other fluid which is readily absorbed by the tissue of the lumen walls 104 and which readily absorbs RF energy. In further alternative embodiments, the treatment fluid 1 12 may comprise medicine, water, or a fluid which is relatively inert and non-bioreactive but heat conductive.
Balloons The tip assembly 101 also includes a first occluding balloon 106 preferably disposed at or near a proximal end 109 of the tip assembly 101 , and a second occluding balloon 107 preferably disposed at or near the distal end 1 10 of the tip assembly 101. The occluding balloons 106 and 107 are disposed so that when inflated, and in
combination with the body of the tip assembly 101, they form a gas-tight or fluid-tight seal against the lumen walls 105 and seal off the portion of the dilatation 1 13 to be treated from other portions of the lumen 104. The occluding balloons 106 and 107 preferably comprise ring-shaped annular balloons; however, in an alternative embodiment, the distal occluding balloon 107 may comprise a spherical or ellipsoidal balloon disposed at the distal end 1 10 of the tip assembly 101 in such a manner that when inflated it surrounds the catheter 100 and makes a gas-tight or fluid-tight seal against the lumen walls 104.
In a preferred embodiment, both occluding balloons 106 and 107 are coupled to a single lumen in the catheter tube 102 disposed for delivery of an inflation fluid from a source (not shown). In an alternative embodiment, the occluding balloons 106 and 107 are coupled to separate lumina in the catheter tube 102 disposed for delivery of inflation fluid from sources (not shown), so that the occluding balloons 106 and 107 may be inflated independently of each other. In a preferred embodiment, at least one occluding balloon 106 or 107 is disposed to anchor the catheter 100 at a selected location within the lumen 104; alternatively, both occluding balloons 106 and 107 may be to anchor the catheter 100. The occluding balloons 106 and 107 when inflated prevent the catheter 100 from being expelled from the body in like manner as the operation of a Foley catheter. However, in alternative embodiments, the balloon used to anchor the catheter 100 may comprise either occluding balloon 106 or 107, or an additional or alternative balloon which is disposed solely or primarily for the purpose of anchoring the catheter 100 into the selected location, again in like manner as the operation of a Foley catheter.
The tip assembly 101 may also include a third balloon 108 (hereinafter referred to as a "treatment balloon 108"), preferably located intermediately between the occluding balloons 106 and 107, which is inflated using a lumen in the catheter tube 102 for delivery of treatment fluid 1 12 from a source (not shown) through at least one port 1 1 1. In a preferred embodiment, the treatment balloon 108 is disposed so that when inflated its surface physically comes into contact with the tissue of the lumen walls 105 which comprise the dilatation 1 13. The treatment balloon 108 may also include a porous, microporous, or semiporous membrane through which the treatment fluid 1 12 may flow.
In an embodiment wherein a treatment balloon 108 is used, the suction ports 1 14 are preferably located between the outside surface of intermediate treatment balloon 108 and the outside surfaces of the occluding balloons 106 and/or 107, so that the fluid is drawn into the suction ports 1 14 from the occluded region of the lumen 104. Preferably, the suction ports 1 14 may be used either separately or at the same time that treatment fluid 1 12 is delivered from the ports 1 1 1 into the treatment balloon 108.
Electrodes
The catheter 1 10 also includes at least one electrode, described in more detail below, preferably disposed on the tip assembly 101 between the occluding balloons 106 and 107. The electrodes are coupled using the catheter tube 102 to a power source 120. The power source 120 provides energy to the electrodes, which emit that energy into the lumen walls 105 of the dilatation 1 13 which have been perfused with the treatment fluid 1 12 so as to affect the lumen walls 105 of the dilatation 1 13. Fig. 3 shows a first aspect of the preferred embodiment using direct contact bipolar electrodes 123 to emit RF energy for heating, ablation and/or shrinkage of the dilatation 1 13. In the first aspect of the preferred embodiment, a plurality of bipolar electrodes 123 are distributed more or less equidistant from each other and disposed so that when the treatment balloon 108 is inflated the electrodes 123 are put in direct contact with the inner surface of the lumen walls 105 in the occluded region of the dilatation 1 13. In a preferred embodiment, the electrodes 123 are disposed on an expandable conductor mesh 122 surrounding around the treatment balloon 108. In an alternative embodiment, the conductor mesh 122 and electrodes 123 may be disposed in or near the surface of the treatment balloon 108. Fig.4 shows a second aspect of the preferred embodiment using monopolar ring electrodes 124 to emit RF energy for heating, ablation and shrinkage of the dilatation 1 13. In the second aspect of the preferred embodiment, a plurality of monopolar ring electrodes 124 are disposed repeatedly on or near the surface of the tip assembly 101 between its proximal end 109 and distal end 1 10. Fig. 5 shows a third aspect of the preferred embodiment using bipolar ring electrodes 125 to emit RF energy for heating, ablation and shrinkage of the dilatation 1 13. In the third aspect of the preferred embodiment, a plurality of bipolar ring
electrodes 125 are disposec repeatedly on or near the surface of the tip assembly 101 between the proximal end 109 and the distal end 110 of the tip assembly 101.
In alternative embodiments, many configurations of electrodes and sensors 1 16 may operate under processor control to achieve such effects. In a first example, distances between pairs of ring electrodes 124 may be adjusted, either during manufacture, dynamically before use of the catheter tip 101 , or otherwise. In a second example, the sensors 1 16 may be effective to measure other dynamic features of the treatment fluid 1 12 and lumen-wall tissue of the dilatation 113, such as a localized electrical impedance, a localized fluid flow, or some combination thereof. In a third example, the processor may be effective to control other features of the RF energy, such as a pulse shape or duty cycle of a pulse for RF energy delivery, a frequency for RF energy delivery, a time duration for pulses or time duration between pulses, an order for selection of individual ring electrodes 120 for delivery of RF energy, or some combination thereof.
Energy Source
Electrodes, as described above, are coupled to a power source 120 using a conductor 121 in the catheter tube 102. The conductor 121 is preferably insulated so as to avoid electrical coupling with the catheter tube 102, the treatment fluid 1 12 or the lumen walls 105. The power source 120 provides energy to the electrodes, which emit that energy into the treatment fluid 1 12 and tissue of the lumen walls 105 in the occluded region of the dilatation 1 13.
As used herein, the term "RF energy" is used generically to mean and refer to any means for heating the treatment fluid 112 and/or tissue of the lumen walls 105, broadly including the application of RF energy in a wide range of frequencies, such as the 300 to 700 MHz frequency described herein as well as other microwave frequencies and other frequencies. Those skilled in the art would recognize, after perusal of this application, that other means for heating the treatment fluid 1 12 and lumen walls 105 may be applied. For example, where the treatment fluid 112 is a photosensitive substance, the means for heating may comprise light. In such an alternative embodiment, the light may be delivered by a laser, light-emitting diode, or other light source coupled to the tip assembly 101.
The energy source 120 is preferably located outside the lumen 104 and outside the body. In a preferred embodiment, the RF energy source 120 generates a continuous or pulsed waveform, preferably a sinusoidal waveform or a square waveform, such as an RF energy generator available as a standard product from Radionics Valley Laboratories, a division of Pfizer, Inc.
In a preferred embodiment, the RF energy source 120 supplies about 50 watts of power, distributed to all of the electrodes 123 collectively, and pulsed in a round- robm fashion among the electrodes 123 so as to equally distribute the delivered energy to all positions along the tip assembly 101 The RF energy source 120 may comprise a processor which is responsive to signals from the sensors 1 16 and to a computed or expected amount of the treatment fluid 1 12 and lumen wall tissue 105 to be treated The processoi computes an effective amount of time and RF energy to deliver to each individual electrode, and controls delivery of RF energy to each individual electrode so as to deliver RF energy to localized points of the treatment fluid 1 12 and lumen wall tissues 105 which have absorbed it
Method of Operation Figure 6 shows a flowchart for a method of operation of the catheter 100 A method 200 of operation for the catheter 100 comprises a sequence of steps between the flow points 201 and 220. In the preferred embodiment, the method 200 is carried out using the catheter 100, as well as other and furthei equipment which would be cleaily deemed necessary or desirable by those skilled in the art
At a flow point 201 , the catheter 100 is ready for use to treat dilatation 1 1 At a step 202 in a preferred embodiment, the catheter 100 is inserted into the lumen 104 of a patient at a natural body orifice such as the mouth, anus or urethra However, in alternative embodiments the catheter 100 may be inserted into a blood vessel near a body surface, such as the jugular vein or carotid artery or other blood vessel in the neck, or may be inserted into the patient at a body structure which is made available during surgery or by virtue of a wound, the body structure may comprise a blood vessel, tubular organ, the lymphatic system, a smus cavity or other ear/nose/throat structure, the intestines, the urethra, a mass of tissue such as a cyst or a fatty deposit, or some other body structure.
At a step 203, the catheter 100 is maneuvered by an operator (not shown) to a position in the lumen 104 approximately adjacent to the dilatation 113 while the operator views the position of the catheter 100 using fluoroscopy, ultrasound, or other suitable means. At a step 204, the occluding balloons 106 and 107 are inflated and the dilatation
113 sealed off from the remainder of the lumen 104.
At a step 205, the treatment balloon 108 is inflated with treatment fluid 1 12 exuded from ports 1 1 1 while simultaneously any body fluids in the occluded dilatation 1 13 are removed by suctioning them into suction ports 1 14 disposed on the tip assembly 101 between the occluding balloons 106 and 107 and coupled to a suction lumen in the catheter tube 102. Body fluids are thus removed from the occluded portion of the dilatation 1 13 by the dual action of suction outside the treatment balloon 108 and pressure within it. Inflation of the treatment balloon 108 and suction of body fluids continues until all body fluids have been removed from the occluded dilatation 1 13 and the outer surface of the treatment balloon 108 has been brought into contact with the inner surface of the lumen wall 105 of the dilatation 1 13.
At a step 206, RF energy is emitted by electrodes in the catheter tip assembly 101 at a selected frequency and power level effective to heat the treatment fluid 112 to a temperature at which it is readily absorbable into the tissue of the lumen walls 105. At a step 207, the treatment fluid 1 12 in the treatment balloon 108 is pressurized to a selected pressure, effective to cause the treatment fluid 1 12 to exude through the microporous membrane of the treatment balloon and come into contact with the lumen walls 105.
At a step 208, the heated treatment fluid 112 is suffused into and absorbed by the tissues of the lumen walls 105.
At a step 209, additional RF energy is emitted by the electrodes in the catheter tip assembly 101 at a selected frequency and power level effective to preferentially heat tissues of the lumen walls 105 which have absorbed the treatment fluid 1 12. Optionally, while tissues of the lumen walls 105 are being heated, cool treatment fluid 112 may be circulated in the occluded portion of the lumen 104 by exuding it from ports 1 1 1 and suctioning it into suction ports 1 14, in order to minimize heating and damage of cells lining the inner surface of the lumen walls 105. Heating of lumen wall tissues 105 continues until they have been softened.
At a step 210, the heated treatment fluid 112 is removed from the occluded portion of the dilatation 113 via the suction ports 114 and the occluded portion of the dilatation is filled with chilled treatment fluid 112 via the ports 1 11.
At a step 212, the dilatation 113 is contracted by application of the chilled treatment fluid 112 and by application of a vacuum via the suction ports 1 14 so that dilatation 1 13 shrinks to a diameter within a normal diameter range for the lumen 104.
At a step 213, additional RF energy may be emitted by the electrodes in the catheter tip assembly 101 at a selected frequency and power level effective to ablate tissues of the lumen walls 105, while chilled treatment fluid 1 12 is circulated by exuding it in via the ports 111 and suctioning it out via the suction ports 1 14 in order to minimize heating and damage of cells lining the inner surface of the lumen walls 105 and remove detritus of ablation.
At a step 214, the tissues of the lumen walls 105 are hardened in the contracted condition by further application of RF energy and circulation of chilled treatment fluid 112.
At a step 215, the occluding balloons 106 and 107 and the treatment balloon 108 are deflated.
At a step 216, the catheter 100 is removed from the body of the patient.
At a flow point 220, the dilatation has been treated and should be in a condition for normal operation.
Alternative Embodiments Although preferred embodiments are disclosed herein, many variations are possible which remain within the concept, scope, and spirit of the invention, and these variations would become clear to those skilled in the art after perusal of this application.
Claims
1. A method for treating a dilatation of a body, including the steps of: inserting a catheter into a localized region of said body; exuding from said catheter a substance capable of perfusing into at least some tissue in said localized region; allowing said substance to perfuse into a tissue of said localized region; emitting from said catheter energy of a frequency and in an amount effective to cause a temperature change in said substance; whereby, at least some tissue in said localized region is treated.
2. A method as in claim 1 , wherein said localized region includes a lumen or sphincter.
3. A method as in claim 1 , wherein said localized region includes cancerous, engorged, inflamed or infected tissue.
4. A method as in claim 1, wherein said localized region includes an aneurysm, a blocked lumen, a stenosed lumen or a constricted lumen.
5. A method as in claim 1 , wherein said localized region includes a cyst, tumor or wart.
6. A method as in claim 1 , wherein said localized region is associated with a body system, said body system including a blood vessel, lung tube, lung pocket, gastrointestinal system, urogenital system, nerve or nerve sheath.
7. A method as in claim 1 , wherein said localized region is associated with a particular organ including a kidney, prostate, retinal lesion or skin lesion.
8. A method as in claim 1 , wherein said exuded substance includes a saline solution.
9. A method as in claim 1 , wherein said exuded substance includes a nontoxic foam.
10. A method as in claim 1 , wherein said exuded substance includes a collagen.
1 1. A method as in claim 1 , wherein said exuded substance includes a bioactive substance, said substance including a drug or enzyme.
12. A method as in claim 1 , wherein said exuded substance includes a chemoactive substance including an acid, lipid-breaker or soap.
13. A method as in claim 1 , wherein said exuded substance includes an instrumentative substance including a florescent or x-ray marker.
14. A method as in claim 1 , wherein said energy is emitted by electrical contact.
15. A method as in claim 1 , wherein said emitted energy includes RF (monopolar or bipolar), microwave or laser.
16. A method as in claim 1 , wherein said emitted energy includes ultrasound.
17. A method as in claim 1 , wherein said emitted energy includes physical heating or cooling.
18. A method as in claim 1 , wherein said treatment includes shrinkage of said lumen or said sphincter to a selected dimension.
19. A method as in claim 1 , wherein said treatment includes shrinkage of said lumen or said sphincter to a substantially normal dimension.
20. A method as in claim 1, wherein said treatment includes shrinkage of said engorged or inflamed tissue by removal of lipids or water.
21. A method as in claim 1 , wherein said treatment includes shrinkage of said engorged or inflamed tissue by removal of an ablated tissue or a dead cell matter.
22. A method as in claim 1 , wherein said treatment includes shrinkage of said engorged or inflamed tissue by removal of infection products.
23. A method as in claim 1 , wherein said treatment includes destruction of a damaged or a diseased tissue.
24. A method as in claim 1 , wherein said treatment includes promotion of epithelial growth.
25. A method as in claim 1 , wherein said treatment avoids local nerve centers.
26. A method as in claim 1 , including an additional step of isolating said localized region using a structure inserted as part of said catheter.
27. A method as in claim 26, wherein said inserted structure includes an occluding balloon.
28. A method as in claim 26, wherein said inserted structure includes a space-filling balloon with a lumen through it.
29. A method as in claim 1 , wherein said catheter includes instrumentation used for feedback.
30. A method as in claim 29, wherein said feedback includes surgical visualization provided by a camera, RF energy, x-rays, florescence or ultrasound.
31. A method as in claim 29, wherein said feedback includes systemic, comprising measurement of pH, pressure or temperature.
32. A method as in claim 29, wherein said feedback includes monitoring for said treatment, including an element for determining a location of a specified tissue element to be treated.
33. A method as in claim 29, wherein said feedback includes monitoring for said treatment, including pacing.
34. A method as in claim 1 , wherein said exuding and perfusing includes a physical method of delivery.
35. A method as in claim 34, wherein said exuded and perfused substance includes included in a saline solution or nontoxic foam.
36. A method as in claim 34, wherein said physical method of delivery includes a porous balloon, a microporous balloon, or a balloon with a porous or microporous membrane.
37. A method as in claim 34, wherein said physical method of delivery includes direct emission from said catheter.
38. A method as in claim 34, wherein said physical method of delivery includes a local structure, comprising an absorbable basket or a stent.
1023684
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02020629A EP1264613B1 (en) | 2000-01-24 | 2001-01-24 | Catheter for shrinkage of dilations in the body |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US490622 | 1983-05-02 | ||
US09/490,622 US7184827B1 (en) | 2000-01-24 | 2000-01-24 | Shrinkage of dilatations in the body |
PCT/US2001/002428 WO2001052930A1 (en) | 2000-01-24 | 2001-01-24 | Shrinkage of dilatations in the body |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02020629A Division EP1264613B1 (en) | 2000-01-24 | 2001-01-24 | Catheter for shrinkage of dilations in the body |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1250170A1 true EP1250170A1 (en) | 2002-10-23 |
Family
ID=23948829
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02020629A Expired - Lifetime EP1264613B1 (en) | 2000-01-24 | 2001-01-24 | Catheter for shrinkage of dilations in the body |
EP01902144A Withdrawn EP1250170A1 (en) | 2000-01-24 | 2001-01-24 | Shrinkage of dilatations in the body |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02020629A Expired - Lifetime EP1264613B1 (en) | 2000-01-24 | 2001-01-24 | Catheter for shrinkage of dilations in the body |
Country Status (8)
Country | Link |
---|---|
US (1) | US7184827B1 (en) |
EP (2) | EP1264613B1 (en) |
JP (1) | JP2004500184A (en) |
AT (1) | ATE354397T1 (en) |
AU (1) | AU2001227975A1 (en) |
CA (1) | CA2390800A1 (en) |
DE (1) | DE60126748T2 (en) |
WO (1) | WO2001052930A1 (en) |
Families Citing this family (181)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8353908B2 (en) | 1996-09-20 | 2013-01-15 | Novasys Medical, Inc. | Treatment of tissue in sphincters, sinuses, and orifices |
US9023031B2 (en) * | 1997-08-13 | 2015-05-05 | Verathon Inc. | Noninvasive devices, methods, and systems for modifying tissues |
US20100114087A1 (en) * | 1998-02-19 | 2010-05-06 | Edwards Stuart D | Methods and devices for treating urinary incontinence |
US7229469B1 (en) | 1999-10-02 | 2007-06-12 | Quantumcor, Inc. | Methods for treating and repairing mitral valve annulus |
US20040215235A1 (en) | 1999-11-16 | 2004-10-28 | Barrx, Inc. | Methods and systems for determining physiologic characteristics for treatment of the esophagus |
US6551310B1 (en) * | 1999-11-16 | 2003-04-22 | Robert A. Ganz | System and method of treating abnormal tissue in the human esophagus |
US7306591B2 (en) | 2000-10-02 | 2007-12-11 | Novasys Medical, Inc. | Apparatus and methods for treating female urinary incontinence |
DE10105592A1 (en) | 2001-02-06 | 2002-08-08 | Achim Goepferich | Placeholder for drug release in the frontal sinus |
US8347891B2 (en) | 2002-04-08 | 2013-01-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen |
US7756583B2 (en) | 2002-04-08 | 2010-07-13 | Ardian, Inc. | Methods and apparatus for intravascularly-induced neuromodulation |
US7653438B2 (en) | 2002-04-08 | 2010-01-26 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
US8317816B2 (en) | 2002-09-30 | 2012-11-27 | Acclarent, Inc. | Balloon catheters and methods for treating paranasal sinuses |
AU2003302387A1 (en) | 2002-11-26 | 2004-06-18 | Crosscart, Inc. | Substantially non-immunogenic injectable collagen |
DE202004021949U1 (en) | 2003-09-12 | 2013-05-27 | Vessix Vascular, Inc. | Selectable eccentric remodeling and / or ablation of atherosclerotic material |
US20060063973A1 (en) | 2004-04-21 | 2006-03-23 | Acclarent, Inc. | Methods and apparatus for treating disorders of the ear, nose and throat |
US8747389B2 (en) | 2004-04-21 | 2014-06-10 | Acclarent, Inc. | Systems for treating disorders of the ear, nose and throat |
US8702626B1 (en) | 2004-04-21 | 2014-04-22 | Acclarent, Inc. | Guidewires for performing image guided procedures |
US7361168B2 (en) | 2004-04-21 | 2008-04-22 | Acclarent, Inc. | Implantable device and methods for delivering drugs and other substances to treat sinusitis and other disorders |
US7410480B2 (en) | 2004-04-21 | 2008-08-12 | Acclarent, Inc. | Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders |
US9554691B2 (en) | 2004-04-21 | 2017-01-31 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
US7559925B2 (en) | 2006-09-15 | 2009-07-14 | Acclarent Inc. | Methods and devices for facilitating visualization in a surgical environment |
US7654997B2 (en) | 2004-04-21 | 2010-02-02 | Acclarent, Inc. | Devices, systems and methods for diagnosing and treating sinusitus and other disorders of the ears, nose and/or throat |
US7419497B2 (en) | 2004-04-21 | 2008-09-02 | Acclarent, Inc. | Methods for treating ethmoid disease |
US8932276B1 (en) | 2004-04-21 | 2015-01-13 | Acclarent, Inc. | Shapeable guide catheters and related methods |
US7803150B2 (en) | 2004-04-21 | 2010-09-28 | Acclarent, Inc. | Devices, systems and methods useable for treating sinusitis |
US20060004323A1 (en) | 2004-04-21 | 2006-01-05 | Exploramed Nc1, Inc. | Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures |
US10188413B1 (en) | 2004-04-21 | 2019-01-29 | Acclarent, Inc. | Deflectable guide catheters and related methods |
US9101384B2 (en) | 2004-04-21 | 2015-08-11 | Acclarent, Inc. | Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, Nose and/or throat |
US9089258B2 (en) | 2004-04-21 | 2015-07-28 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
US8764729B2 (en) | 2004-04-21 | 2014-07-01 | Acclarent, Inc. | Frontal sinus spacer |
US9351750B2 (en) | 2004-04-21 | 2016-05-31 | Acclarent, Inc. | Devices and methods for treating maxillary sinus disease |
US9399121B2 (en) | 2004-04-21 | 2016-07-26 | Acclarent, Inc. | Systems and methods for transnasal dilation of passageways in the ear, nose or throat |
US20190314620A1 (en) | 2004-04-21 | 2019-10-17 | Acclarent, Inc. | Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures |
US8894614B2 (en) | 2004-04-21 | 2014-11-25 | Acclarent, Inc. | Devices, systems and methods useable for treating frontal sinusitis |
US8146400B2 (en) | 2004-04-21 | 2012-04-03 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
US7462175B2 (en) | 2004-04-21 | 2008-12-09 | Acclarent, Inc. | Devices, systems and methods for treating disorders of the ear, nose and throat |
US20070167682A1 (en) | 2004-04-21 | 2007-07-19 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
US20070208252A1 (en) | 2004-04-21 | 2007-09-06 | Acclarent, Inc. | Systems and methods for performing image guided procedures within the ear, nose, throat and paranasal sinuses |
US20060085054A1 (en) * | 2004-09-09 | 2006-04-20 | Zikorus Arthur W | Methods and apparatus for treatment of hollow anatomical structures |
US9713730B2 (en) | 2004-09-10 | 2017-07-25 | Boston Scientific Scimed, Inc. | Apparatus and method for treatment of in-stent restenosis |
US8396548B2 (en) | 2008-11-14 | 2013-03-12 | Vessix Vascular, Inc. | Selective drug delivery in a lumen |
US8920414B2 (en) | 2004-09-10 | 2014-12-30 | Vessix Vascular, Inc. | Tuned RF energy and electrical tissue characterization for selective treatment of target tissues |
US9125667B2 (en) | 2004-09-10 | 2015-09-08 | Vessix Vascular, Inc. | System for inducing desirable temperature effects on body tissue |
ATE542486T1 (en) | 2005-03-28 | 2012-02-15 | Minnow Medical Llc | INTRALUMINAL ELECTRICAL TISSUE CHARACTERIZATION AND TUNED RF ENERGY FOR SELECTIVE TREATMENT OF ATHEROMA AND OTHER TARGET TISSUES |
US8951225B2 (en) | 2005-06-10 | 2015-02-10 | Acclarent, Inc. | Catheters with non-removable guide members useable for treatment of sinusitis |
US8114113B2 (en) | 2005-09-23 | 2012-02-14 | Acclarent, Inc. | Multi-conduit balloon catheter |
US8019435B2 (en) | 2006-05-02 | 2011-09-13 | Boston Scientific Scimed, Inc. | Control of arterial smooth muscle tone |
US8190389B2 (en) | 2006-05-17 | 2012-05-29 | Acclarent, Inc. | Adapter for attaching electromagnetic image guidance components to a medical device |
US9820688B2 (en) | 2006-09-15 | 2017-11-21 | Acclarent, Inc. | Sinus illumination lightwire device |
ES2560006T3 (en) | 2006-10-18 | 2016-02-17 | Vessix Vascular, Inc. | Induction of desirable temperature effects on body tissue |
US8439687B1 (en) | 2006-12-29 | 2013-05-14 | Acclarent, Inc. | Apparatus and method for simulated insertion and positioning of guidewares and other interventional devices |
US10463886B2 (en) | 2007-02-22 | 2019-11-05 | Ramot At Tel-Aviv University Ltd. | Treating weakened vessel wall such as vulnerable plaque or aneurysms |
WO2008124787A2 (en) | 2007-04-09 | 2008-10-16 | Acclarent, Inc. | Ethmoidotomy system and implantable spacer devices having therapeutic substance delivery capability for treatment of paranasal sinusitis |
US8496653B2 (en) | 2007-04-23 | 2013-07-30 | Boston Scientific Scimed, Inc. | Thrombus removal |
US8118757B2 (en) | 2007-04-30 | 2012-02-21 | Acclarent, Inc. | Methods and devices for ostium measurement |
US8641711B2 (en) * | 2007-05-04 | 2014-02-04 | Covidien Lp | Method and apparatus for gastrointestinal tract ablation for treatment of obesity |
US8485199B2 (en) | 2007-05-08 | 2013-07-16 | Acclarent, Inc. | Methods and devices for protecting nasal turbinate during surgery |
WO2009009443A1 (en) | 2007-07-06 | 2009-01-15 | Barrx Medical, Inc. | Method and apparatus for gastrointestinal tract ablation to achieve loss of persistent and/or recurrent excess body weight following a weight-loss operation |
BRPI0813579A2 (en) * | 2007-07-06 | 2014-12-30 | Barrx Medical Inc | Methods for treating a bleeding area in a gastrointestinal tract and ablatively treating a target site within a bleeding area of a gastrointestinal tract and ablation system. |
US20090012518A1 (en) * | 2007-07-06 | 2009-01-08 | Utley David S | Method and Apparatus for Ablation of Benign, Pre-Cancerous and Early Cancerous Lesions That Originate Within the Epithelium and are Limited to the Mucosal Layer of the Gastrointestinal Tract |
US20090054922A1 (en) * | 2007-08-23 | 2009-02-26 | Broker Harshal S | Apparatus and Method for the Intravascular Control of Trauma |
US20100198191A1 (en) | 2007-12-20 | 2010-08-05 | Acclarent, Inc. | Method and system for treating target tissue within the eustachian tube |
US10206821B2 (en) | 2007-12-20 | 2019-02-19 | Acclarent, Inc. | Eustachian tube dilation balloon with ventilation path |
US8182432B2 (en) | 2008-03-10 | 2012-05-22 | Acclarent, Inc. | Corewire design and construction for medical devices |
MX2011001099A (en) | 2008-07-30 | 2011-03-15 | Acclarent Inc | Paranasal ostium finder devices and methods. |
DE102008045038A1 (en) * | 2008-08-29 | 2010-03-04 | Osypka, Peter, Dr.- Ing. | Device for ablating the mouth of the pulmonary veins |
CN102159276B (en) | 2008-09-18 | 2014-01-15 | 阿克拉伦特公司 | Method and device for treating ENT diseases |
AU2009314133B2 (en) | 2008-11-17 | 2015-12-10 | Vessix Vascular, Inc. | Selective accumulation of energy with or without knowledge of tissue topography |
US20100241155A1 (en) | 2009-03-20 | 2010-09-23 | Acclarent, Inc. | Guide system with suction |
US8435290B2 (en) | 2009-03-31 | 2013-05-07 | Acclarent, Inc. | System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx |
US7978742B1 (en) | 2010-03-24 | 2011-07-12 | Corning Incorporated | Methods for operating diode lasers |
US8551096B2 (en) | 2009-05-13 | 2013-10-08 | Boston Scientific Scimed, Inc. | Directional delivery of energy and bioactives |
CA2759817A1 (en) * | 2009-06-05 | 2010-12-09 | Entrigue Surgical, Inc. | Systems and devices for providing therapy of an anatomical structure |
CA2788082C (en) * | 2010-01-28 | 2018-02-20 | Art Healthcare Ltd. | Method and device of detecting and/or blocking reflux |
AU2011238925B2 (en) | 2010-04-09 | 2016-06-16 | Vessix Vascular, Inc. | Power generating and control apparatus for the treatment of tissue |
US9192790B2 (en) | 2010-04-14 | 2015-11-24 | Boston Scientific Scimed, Inc. | Focused ultrasonic renal denervation |
US8473067B2 (en) | 2010-06-11 | 2013-06-25 | Boston Scientific Scimed, Inc. | Renal denervation and stimulation employing wireless vascular energy transfer arrangement |
US9463062B2 (en) | 2010-07-30 | 2016-10-11 | Boston Scientific Scimed, Inc. | Cooled conductive balloon RF catheter for renal nerve ablation |
US9155589B2 (en) | 2010-07-30 | 2015-10-13 | Boston Scientific Scimed, Inc. | Sequential activation RF electrode set for renal nerve ablation |
US9084609B2 (en) | 2010-07-30 | 2015-07-21 | Boston Scientific Scime, Inc. | Spiral balloon catheter for renal nerve ablation |
US9408661B2 (en) | 2010-07-30 | 2016-08-09 | Patrick A. Haverkost | RF electrodes on multiple flexible wires for renal nerve ablation |
US9358365B2 (en) | 2010-07-30 | 2016-06-07 | Boston Scientific Scimed, Inc. | Precision electrode movement control for renal nerve ablation |
US10589071B2 (en) | 2010-09-23 | 2020-03-17 | Best Medical International, Inc. | Multiple function balloon catheter |
US10744307B2 (en) | 2010-09-23 | 2020-08-18 | Best Medical International, Inc. | Multi-purpose balloon catheter for intra cavity radiation delivery |
US9155492B2 (en) | 2010-09-24 | 2015-10-13 | Acclarent, Inc. | Sinus illumination lightwire device |
US8974451B2 (en) | 2010-10-25 | 2015-03-10 | Boston Scientific Scimed, Inc. | Renal nerve ablation using conductive fluid jet and RF energy |
US9220558B2 (en) | 2010-10-27 | 2015-12-29 | Boston Scientific Scimed, Inc. | RF renal denervation catheter with multiple independent electrodes |
US9028485B2 (en) | 2010-11-15 | 2015-05-12 | Boston Scientific Scimed, Inc. | Self-expanding cooling electrode for renal nerve ablation |
US9668811B2 (en) | 2010-11-16 | 2017-06-06 | Boston Scientific Scimed, Inc. | Minimally invasive access for renal nerve ablation |
US9089350B2 (en) | 2010-11-16 | 2015-07-28 | Boston Scientific Scimed, Inc. | Renal denervation catheter with RF electrode and integral contrast dye injection arrangement |
US9326751B2 (en) | 2010-11-17 | 2016-05-03 | Boston Scientific Scimed, Inc. | Catheter guidance of external energy for renal denervation |
US9060761B2 (en) | 2010-11-18 | 2015-06-23 | Boston Scientific Scime, Inc. | Catheter-focused magnetic field induced renal nerve ablation |
US9023034B2 (en) | 2010-11-22 | 2015-05-05 | Boston Scientific Scimed, Inc. | Renal ablation electrode with force-activatable conduction apparatus |
US9192435B2 (en) | 2010-11-22 | 2015-11-24 | Boston Scientific Scimed, Inc. | Renal denervation catheter with cooled RF electrode |
US20120157993A1 (en) | 2010-12-15 | 2012-06-21 | Jenson Mark L | Bipolar Off-Wall Electrode Device for Renal Nerve Ablation |
KR20230145213A (en) | 2011-01-19 | 2023-10-17 | 프랙틸 헬쓰, 인코포레이티드 | Devices and methods for the treatment of tissue |
WO2012100095A1 (en) | 2011-01-19 | 2012-07-26 | Boston Scientific Scimed, Inc. | Guide-compatible large-electrode catheter for renal nerve ablation with reduced arterial injury |
JP5759615B2 (en) | 2011-04-08 | 2015-08-05 | コヴィディエン リミテッド パートナーシップ | Iontophoretic catheter system and method for renal sympathetic denervation and iontophoretic drug delivery |
EP2701623B1 (en) | 2011-04-25 | 2016-08-17 | Medtronic Ardian Luxembourg S.à.r.l. | Apparatus related to constrained deployment of cryogenic balloons for limited cryogenic ablation of vessel walls |
CN103813745B (en) | 2011-07-20 | 2016-06-29 | 波士顿科学西美德公司 | In order to visualize, be directed at and to melt transcutaneous device and the method for nerve |
AU2012287189B2 (en) | 2011-07-22 | 2016-10-06 | Boston Scientific Scimed, Inc. | Nerve modulation system with a nerve modulation element positionable in a helical guide |
US9186210B2 (en) | 2011-10-10 | 2015-11-17 | Boston Scientific Scimed, Inc. | Medical devices including ablation electrodes |
WO2013055815A1 (en) | 2011-10-11 | 2013-04-18 | Boston Scientific Scimed, Inc. | Off -wall electrode device for nerve modulation |
US9420955B2 (en) | 2011-10-11 | 2016-08-23 | Boston Scientific Scimed, Inc. | Intravascular temperature monitoring system and method |
US9364284B2 (en) | 2011-10-12 | 2016-06-14 | Boston Scientific Scimed, Inc. | Method of making an off-wall spacer cage |
US9079000B2 (en) | 2011-10-18 | 2015-07-14 | Boston Scientific Scimed, Inc. | Integrated crossing balloon catheter |
US9162046B2 (en) | 2011-10-18 | 2015-10-20 | Boston Scientific Scimed, Inc. | Deflectable medical devices |
EP2775948B1 (en) | 2011-11-08 | 2018-04-04 | Boston Scientific Scimed, Inc. | Ostial renal nerve ablation |
US9119600B2 (en) | 2011-11-15 | 2015-09-01 | Boston Scientific Scimed, Inc. | Device and methods for renal nerve modulation monitoring |
US9119632B2 (en) | 2011-11-21 | 2015-09-01 | Boston Scientific Scimed, Inc. | Deflectable renal nerve ablation catheter |
MX2014006219A (en) * | 2011-11-28 | 2015-06-04 | Urinary Biosolutions Llc | Treatment of urinary incontinence. |
US9265969B2 (en) | 2011-12-21 | 2016-02-23 | Cardiac Pacemakers, Inc. | Methods for modulating cell function |
US9037259B2 (en) | 2011-12-23 | 2015-05-19 | Vessix Vascular, Inc. | Methods and apparatuses for remodeling tissue of or adjacent to a body passage |
CN104135958B (en) | 2011-12-28 | 2017-05-03 | 波士顿科学西美德公司 | By the apparatus and method that have the new ablation catheter modulation nerve of polymer ablation |
US9050106B2 (en) | 2011-12-29 | 2015-06-09 | Boston Scientific Scimed, Inc. | Off-wall electrode device and methods for nerve modulation |
AU2013226062B2 (en) | 2012-02-27 | 2017-10-19 | Fractyl Health, Inc. | Heat ablation systems, devices and methods for the treatment of tissue |
CN103301562B (en) | 2012-03-08 | 2015-08-26 | 财团法人工业技术研究院 | Enzyme treatment method, enzyme treatment apparatus used for the method, and kit comprising the apparatus |
US8403927B1 (en) | 2012-04-05 | 2013-03-26 | William Bruce Shingleton | Vasectomy devices and methods |
KR102231179B1 (en) | 2012-04-19 | 2021-03-22 | 프랙틸 래브러토리스 인코포레이티드 | Tissue expansion devices, systems and methods |
US10660703B2 (en) | 2012-05-08 | 2020-05-26 | Boston Scientific Scimed, Inc. | Renal nerve modulation devices |
EP3714826A1 (en) | 2012-07-30 | 2020-09-30 | Fractyl Laboratories, Inc. | Electrical energy ablation systems and devices for the treatment of tissue |
EP2882362B1 (en) | 2012-08-09 | 2024-01-03 | Fractyl Health, Inc. | Ablation systems, devices and methods for the treatment of tissue |
US10321946B2 (en) | 2012-08-24 | 2019-06-18 | Boston Scientific Scimed, Inc. | Renal nerve modulation devices with weeping RF ablation balloons |
CN104780859B (en) | 2012-09-17 | 2017-07-25 | 波士顿科学西美德公司 | Self-positioning electrode systems and methods for renal neuromodulation |
US10549127B2 (en) | 2012-09-21 | 2020-02-04 | Boston Scientific Scimed, Inc. | Self-cooling ultrasound ablation catheter |
WO2014047411A1 (en) | 2012-09-21 | 2014-03-27 | Boston Scientific Scimed, Inc. | System for nerve modulation and innocuous thermal gradient nerve block |
US20140088584A1 (en) * | 2012-09-26 | 2014-03-27 | Boston Scientific Scimed, Inc. | Medical device balloon catheter |
WO2014055997A1 (en) | 2012-10-05 | 2014-04-10 | Fractyl Laboratories Inc. | Methods, systems and devices for performing multiple treatments on a patient |
EP2906135A2 (en) | 2012-10-10 | 2015-08-19 | Boston Scientific Scimed, Inc. | Renal nerve modulation devices and methods |
US9956033B2 (en) | 2013-03-11 | 2018-05-01 | Boston Scientific Scimed, Inc. | Medical devices for modulating nerves |
US9693821B2 (en) | 2013-03-11 | 2017-07-04 | Boston Scientific Scimed, Inc. | Medical devices for modulating nerves |
US9808311B2 (en) | 2013-03-13 | 2017-11-07 | Boston Scientific Scimed, Inc. | Deflectable medical devices |
WO2014149690A2 (en) | 2013-03-15 | 2014-09-25 | Boston Scientific Scimed, Inc. | Medical devices and methods for treatment of hypertension that utilize impedance compensation |
US9629684B2 (en) | 2013-03-15 | 2017-04-25 | Acclarent, Inc. | Apparatus and method for treatment of ethmoid sinusitis |
CN105473090B (en) | 2013-03-15 | 2019-05-03 | 波士顿科学国际有限公司 | Method and apparatus for reconstructing tissue of or adjacent to a body passage |
US9433437B2 (en) | 2013-03-15 | 2016-09-06 | Acclarent, Inc. | Apparatus and method for treatment of ethmoid sinusitis |
US10265122B2 (en) | 2013-03-15 | 2019-04-23 | Boston Scientific Scimed, Inc. | Nerve ablation devices and related methods of use |
ES2942724T3 (en) | 2013-04-30 | 2023-06-06 | Alcon Inc | Systems for the treatment of eye diseases |
US9763827B2 (en) | 2013-04-30 | 2017-09-19 | Tear Film Innovations, Inc. | Systems and methods for the treatment of eye conditions |
EP3003461B1 (en) | 2013-06-04 | 2019-05-01 | Fractyl Laboratories, Inc. | Systems and devices for reducing the luminal surface area of the gastrointestinal tract |
JP2016524949A (en) | 2013-06-21 | 2016-08-22 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | Medical device for renal nerve ablation having a rotatable shaft |
JP2016523147A (en) | 2013-06-21 | 2016-08-08 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | Renal denervation balloon catheter with a riding-type electrode support |
US9707036B2 (en) | 2013-06-25 | 2017-07-18 | Boston Scientific Scimed, Inc. | Devices and methods for nerve modulation using localized indifferent electrodes |
US9833283B2 (en) | 2013-07-01 | 2017-12-05 | Boston Scientific Scimed, Inc. | Medical devices for renal nerve ablation |
US10413357B2 (en) | 2013-07-11 | 2019-09-17 | Boston Scientific Scimed, Inc. | Medical device with stretchable electrode assemblies |
CN105377169B (en) | 2013-07-11 | 2019-04-19 | 波士顿科学国际有限公司 | Devices and methods for neuromodulation |
WO2015010074A1 (en) | 2013-07-19 | 2015-01-22 | Boston Scientific Scimed, Inc. | Spiral bipolar electrode renal denervation balloon |
US10342609B2 (en) | 2013-07-22 | 2019-07-09 | Boston Scientific Scimed, Inc. | Medical devices for renal nerve ablation |
EP3024405A1 (en) | 2013-07-22 | 2016-06-01 | Boston Scientific Scimed, Inc. | Renal nerve ablation catheter having twist balloon |
JP6159888B2 (en) | 2013-08-22 | 2017-07-05 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | Flexible circuit with improved adhesion to renal neuromodulation balloon |
CN105555218B (en) | 2013-09-04 | 2019-01-15 | 波士顿科学国际有限公司 | With radio frequency (RF) foley's tube rinsed with cooling capacity |
WO2015038973A1 (en) | 2013-09-12 | 2015-03-19 | Fractyl Laboratories, Inc. | Systems, methods and devices for treatment of target tissue |
EP3043733A1 (en) | 2013-09-13 | 2016-07-20 | Boston Scientific Scimed, Inc. | Ablation balloon with vapor deposited cover layer |
AT514060B1 (en) * | 2013-10-03 | 2014-10-15 | Ami Agency Medical Innovations Gmbh | Device for the treatment of intraluminal injuries to the gastrointestinal tract |
US11246654B2 (en) | 2013-10-14 | 2022-02-15 | Boston Scientific Scimed, Inc. | Flexible renal nerve ablation devices and related methods of use and manufacture |
CN105592778B (en) | 2013-10-14 | 2019-07-23 | 波士顿科学医学有限公司 | High-resolution cardiac mapping electrod-array conduit |
EP3057520A1 (en) | 2013-10-15 | 2016-08-24 | Boston Scientific Scimed, Inc. | Medical device balloon |
US9770606B2 (en) | 2013-10-15 | 2017-09-26 | Boston Scientific Scimed, Inc. | Ultrasound ablation catheter with cooling infusion and centering basket |
CN105636538B (en) | 2013-10-18 | 2019-01-15 | 波士顿科学国际有限公司 | Foley's tube with flexible wire and its correlation technique for using and manufacturing |
WO2015061457A1 (en) | 2013-10-25 | 2015-04-30 | Boston Scientific Scimed, Inc. | Embedded thermocouple in denervation flex circuit |
EP3071286B1 (en) | 2013-11-22 | 2024-01-03 | Fractyl Health, Inc. | Systems for the creation of a therapeutic restriction in the gastrointestinal tract |
WO2015103617A1 (en) | 2014-01-06 | 2015-07-09 | Boston Scientific Scimed, Inc. | Tear resistant flex circuit assembly |
US11000679B2 (en) | 2014-02-04 | 2021-05-11 | Boston Scientific Scimed, Inc. | Balloon protection and rewrapping devices and related methods of use |
EP3102136B1 (en) | 2014-02-04 | 2018-06-27 | Boston Scientific Scimed, Inc. | Alternative placement of thermal sensors on bipolar electrode |
US10959774B2 (en) | 2014-03-24 | 2021-03-30 | Fractyl Laboratories, Inc. | Injectate delivery devices, systems and methods |
US10709490B2 (en) | 2014-05-07 | 2020-07-14 | Medtronic Ardian Luxembourg S.A.R.L. | Catheter assemblies comprising a direct heating element for renal neuromodulation and associated systems and methods |
US9757535B2 (en) | 2014-07-16 | 2017-09-12 | Fractyl Laboratories, Inc. | Systems, devices and methods for performing medical procedures in the intestine |
US11185367B2 (en) | 2014-07-16 | 2021-11-30 | Fractyl Health, Inc. | Methods and systems for treating diabetes and related diseases and disorders |
WO2016011269A1 (en) | 2014-07-16 | 2016-01-21 | Fractyl Laboratories, Inc. | Methods and systems for treating diabetes and related diseases and disorders |
WO2016130098A1 (en) * | 2015-02-10 | 2016-08-18 | Ozturk Kayhan | Transesophageal thermal tactile stimulation apparatus |
US11160569B2 (en) * | 2015-09-17 | 2021-11-02 | Texas Heart Institute | Esophageal probes and methods |
DE102015117340B4 (en) * | 2015-10-12 | 2019-03-28 | Adceris Gmbh & Co. Kg | Balloon catheter for endovascular tempering |
CN105214216B (en) * | 2015-11-17 | 2017-11-03 | 中国人民解放军第二军医大学 | The staylace that a kind of SRT auxiliary is used |
US20170157366A1 (en) * | 2015-12-03 | 2017-06-08 | Benny Assif | Urinary catheters, systems and methods for use during treatment of the prostate |
US10974063B2 (en) | 2016-06-30 | 2021-04-13 | Alcon Inc. | Light therapy for eyelash growth |
US11896823B2 (en) | 2017-04-04 | 2024-02-13 | Btl Healthcare Technologies A.S. | Method and device for pelvic floor tissue treatment |
WO2019089392A1 (en) * | 2017-10-30 | 2019-05-09 | Metaboscopy Medical, Inc. | Diabetes treatment methods and devices |
CN113226206A (en) * | 2018-10-17 | 2021-08-06 | 佛罗里达大学研究基金会 | Controlling esophageal temperature during cardiac ablation |
IT201900001223A1 (en) * | 2019-01-28 | 2020-07-28 | I Vasc Srl | Catheter handpiece, catheter and method |
US20220339402A1 (en) * | 2021-04-23 | 2022-10-27 | Ohio State Innovation Foundation | Tunneled Intravascular Catheters, Catheter Systems, and Related Methods |
JP7410199B2 (en) * | 2022-02-28 | 2024-01-09 | 日本ライフライン株式会社 | Balloon electrode catheter |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0165993A1 (en) * | 1983-12-27 | 1986-01-02 | The Board Of Trustees Of The Leland Stanford Junior University | Catheter for treatment of tumors and method for using same |
US4587975A (en) | 1984-07-02 | 1986-05-13 | Cardiac Pacemakers, Inc. | Dimension sensitive angioplasty catheter |
US5231995A (en) | 1986-11-14 | 1993-08-03 | Desai Jawahar M | Method for catheter mapping and ablation |
AU4191989A (en) * | 1988-08-24 | 1990-03-23 | Marvin J. Slepian | Biodegradable polymeric endoluminal sealing |
US5843156A (en) | 1988-08-24 | 1998-12-01 | Endoluminal Therapeutics, Inc. | Local polymeric gel cellular therapy |
US4994069A (en) * | 1988-11-02 | 1991-02-19 | Target Therapeutics | Vaso-occlusion coil and method |
US5236413B1 (en) | 1990-05-07 | 1996-06-18 | Andrew J Feiring | Method and apparatus for inducing the permeation of medication into internal tissue |
US5634899A (en) | 1993-08-20 | 1997-06-03 | Cortrak Medical, Inc. | Simultaneous cardiac pacing and local drug delivery method |
US5256141A (en) | 1992-12-22 | 1993-10-26 | Nelson Gencheff | Biological material deployment method and apparatus |
WO1998020939A2 (en) * | 1996-11-15 | 1998-05-22 | Advanced Bio Surfaces, Inc. | Biomaterial system for in situ tissue repair |
US5728068A (en) * | 1994-06-14 | 1998-03-17 | Cordis Corporation | Multi-purpose balloon catheter |
US5505700A (en) | 1994-06-14 | 1996-04-09 | Cordis Corporation | Electro-osmotic infusion catheter |
US5779673A (en) | 1995-06-26 | 1998-07-14 | Focal, Inc. | Devices and methods for application of intraluminal photopolymerized gels |
US5865801A (en) | 1995-07-18 | 1999-02-02 | Houser; Russell A. | Multiple compartmented balloon catheter with external pressure sensing |
US5728066A (en) | 1995-12-13 | 1998-03-17 | Daneshvar; Yousef | Injection systems and methods |
US5846218A (en) | 1996-09-05 | 1998-12-08 | Pharmasonics, Inc. | Balloon catheters having ultrasonically driven interface surfaces and methods for their use |
US5971983A (en) * | 1997-05-09 | 1999-10-26 | The Regents Of The University Of California | Tissue ablation device and method of use |
US5938660A (en) | 1997-06-27 | 1999-08-17 | Daig Corporation | Process and device for the treatment of atrial arrhythmia |
US5916235A (en) * | 1997-08-13 | 1999-06-29 | The Regents Of The University Of California | Apparatus and method for the use of detachable coils in vascular aneurysms and body cavities |
US6645167B1 (en) * | 1999-05-21 | 2003-11-11 | Micro Therapeutics, Inc. | Methods for embolizing vascular sites with an embolizing composition |
-
2000
- 2000-01-24 US US09/490,622 patent/US7184827B1/en not_active Expired - Fee Related
-
2001
- 2001-01-24 CA CA002390800A patent/CA2390800A1/en not_active Abandoned
- 2001-01-24 AU AU2001227975A patent/AU2001227975A1/en not_active Abandoned
- 2001-01-24 EP EP02020629A patent/EP1264613B1/en not_active Expired - Lifetime
- 2001-01-24 JP JP2001552976A patent/JP2004500184A/en active Pending
- 2001-01-24 WO PCT/US2001/002428 patent/WO2001052930A1/en not_active Application Discontinuation
- 2001-01-24 DE DE60126748T patent/DE60126748T2/en not_active Expired - Lifetime
- 2001-01-24 AT AT02020629T patent/ATE354397T1/en active
- 2001-01-24 EP EP01902144A patent/EP1250170A1/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO0152930A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP1264613A3 (en) | 2004-01-28 |
WO2001052930A1 (en) | 2001-07-26 |
AU2001227975A1 (en) | 2001-07-31 |
DE60126748T2 (en) | 2007-12-06 |
EP1264613A2 (en) | 2002-12-11 |
CA2390800A1 (en) | 2001-07-26 |
US7184827B1 (en) | 2007-02-27 |
DE60126748D1 (en) | 2007-04-05 |
EP1264613B1 (en) | 2007-02-21 |
JP2004500184A (en) | 2004-01-08 |
ATE354397T1 (en) | 2007-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7184827B1 (en) | Shrinkage of dilatations in the body | |
US8911430B2 (en) | Medical probes for the treatment of blood vessels | |
US6425853B1 (en) | Treating body tissue by applying energy and substances with a retractable catheter and contained cooling element | |
CN113015495A (en) | Heating steam ablation system and method for treating heart disease | |
US6605055B1 (en) | Balloon catheter with irrigation sheath | |
CA2250603C (en) | Treating urinary and other body strictures | |
CN104739502B (en) | Method and apparatus for tissue ablation | |
US7326235B2 (en) | Treatment of urinary incontinence and other disorders by application of energy and drugs | |
US6425877B1 (en) | Treatment of tissue in the digestive circulatory respiratory urinary and reproductive systems | |
EP1622531B1 (en) | Apparatus for treatment of tissue | |
JP5905397B2 (en) | Multifluid tissue resection method and device | |
US5045056A (en) | Method and device for thermal ablation of hollow body organs | |
US12137969B2 (en) | Heated vapor ablation systems and methods for treating cardiac conditions | |
JP7486427B2 (en) | Devices and methods for deactivating the gallbladder | |
WO2000000100A1 (en) | Endometrial balloon ablation catheter having heater | |
WO2000059393A1 (en) | Treating body tissue by applying energy and substances | |
JP2002513652A (en) | Removal device assembly to be irrigated | |
CN110575251B (en) | Balloon-type flexible microwave ablation catheter and ablation system and method adopting same | |
CN111374753A (en) | ablation balloon catheters that allow blood flow | |
EP1281366B1 (en) | Treatment of sphincters with electrosurgery and active substances | |
KR100898413B1 (en) | Catheter system | |
CN222367753U (en) | Catheter for transmitting shock waves in body lumen | |
UA44790C2 (en) | DEVICE FOR ENDOVASCULAR HYPERTHERMIA AND METHOD OF TREATMENT OF VASCULAR DISEASES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
17P | Request for examination filed |
Effective date: 20020814 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
18W | Application withdrawn |
Withdrawal date: 20021001 |